Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
136
Recruiting, any sponsor type, condition "asthma"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting136
- Completed1,846
136 trials
Showing 1 to 25, recently updated first.
- A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)Pivotal-lookingRecruiting
Generate BiomedicinesIndustry
NCT07359846 · 786 participants (planned) · Start Jan 20, 2026 · Primary completion Jan 2029
Drug: GB-0895; Placebo · For: Severe Asthma
Sites: Bakersfield, California; Inglewood, California; Lancaster, California · 166 sites in all
- Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis_MM09-SIT-069.Pivotal-lookingRecruiting
Inmunotek S.L.Industry
NCT07904195 · 250 participants (planned) · Start Apr 15, 2026 · Primary completion Jul 2029
Drug: EP-088_MM09; Placebo · For: Allergic Rhinitis; Allergic Rhinoconjunctivitis; Allergic Asthma
Sites: Covilha, Portugal; Portimão, Portugal; Ponta Delgada, Portugal · 16 sites in all
- A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)Pivotal-lookingRecruiting
Generate BiomedicinesIndustry
NCT07276724 · 786 participants (planned) · Start Dec 3, 2025 · Primary completion Dec 2028
Drug: GB-0895; Placebo · For: Severe Asthma
Sites: Northridge, California; Pasadena, California; Rancho Cucamonga, California · 158 sites in all
- Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued TreatmentPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07444567 · 230 participants (planned) · Start Jul 24, 2026 · Primary completion Dec 27, 2029
Drug: Benralizumab · For: Asthma; Eosinophilic Granulomatosis With Polyangiitis (EGPA); Hypereosinophilic Syndrome (HES)
Sites: Aurora, Colorado; Bethesda, Maryland; Ann Arbor, Michigan · 46 sites in all
- A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-2)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07782996 · 370 participants (planned) · Start Aug 27, 2026 · Primary completion May 4, 2029
Drug: GSK5784283; Placebo and 1 more · For: Asthma
Sites: San Diego, California; Miami, Florida; Miami Lakes, Florida · 13 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT05222529 · 42 participants (planned) · Start Aug 29, 2022 · Primary completion Jul 30, 2027
Drug: Glycopyrronium bromide 25ug; Placebo and 1 more · For: Asthma
Sites: Rousse, Bulgaria; Sevlievo, Bulgaria; Sofia, Bulgaria · 23 sites in all
- A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe AsthmaPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06023589 · 231 participants (planned) · Start Aug 24, 2023 · Primary completion May 31, 2028
Drug: Tezepelumab · For: Asthma
Sites: Montgomery, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 147 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT05776927 · 188 participants (planned) · Start Aug 4, 2026 · Primary completion Dec 30, 2028
Drug: QVM149; Salmeterol Xinafoate / Fluticasone Propionate and 2 more · For: Asthma
Sites: Rosario, Argentina; Strasbourg, France; Wesel, Germany · 27 sites in all
- A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With AsthmaPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05562466 · 200 participants (planned) · Start May 11, 2023 · Primary completion Feb 1, 2028
Drug: QMF149; Budesonide · For: Asthma
Sites: CABA, Argentina; Mendoza, Argentina; Rosario, Argentina · 65 sites in all
AstraZenecaAstraZeneca (AZN)
NCT06862206 · 700 participants (planned) · Start Jul 11, 2025 · Primary completion Jan 31, 2028
Drug: benralizumab · For: Severe Eosinophilic Asthma
Sites: Anning, China; Beijing, China; Binzhou, China · 36 sites in all
Benjamin MedoffAcademic, hospital or other
NCT00595491 · 313 participants (planned) · Start Jan 2008 · Primary completion Dec 31, 2029
Drug: Bronchoscopy, Segmental Allergen Challenge, and Broncheoalveolar Lavage · For: Asthma
Sites: Boston, Massachusetts
- A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe AsthmaPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT06977581 · 252 participants (planned) · Start May 20, 2025 · Primary completion Mar 8, 2027
Drug: PF-07275315 · For: Asthma
Sites: Mobile, Alabama; Chandler, Arizona; Lancaster, California · 137 sites in all
GlaxoSmithKlineGSK (GSK)
NCT06433921 · 84 participants (planned) · Start Aug 14, 2024 · Primary completion Apr 16, 2027
Drug: Salbutamol HFA-152a; Salbutamol HFA-134a and 1 more · For: Asthma; Mild Asthma
Sites: Manchester, United Kingdom
- A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in AsthmaPivotal-lookingRecruiting
Université de SherbrookeAcademic, hospital or other
NCT07309614 · 150 participants (planned) · Start Jan 29, 2026 · Primary completion Jan 2029
Drug: Dupilumab Prefilled Syringe; Placebo Injection · For: Asthma Control
Sites: Nedlands, Australia; Montreal, Canada; Québec, Canada · 5 sites in all
- A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07645248 · 110 participants (planned) · Start Sep 1, 2026 · Primary completion Dec 28, 2026
Drug: HFA-152a; HFA-134a · For: Asthma
Sites: Aventura, Florida; Miami, Florida; Naples, Florida · 20 sites in all
- A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe AsthmaPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07869043 · 1,100 participants (planned) · Start Sep 30, 2026 · Primary completion Jun 7, 2029
Drug: tilrekimig · For: Asthma
Sites: River Forest, Illinois; Hannibal, Missouri; The Bronx, New York · 12 sites in all
- A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe AsthmaPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07219173 · 531 participants (planned) · Start Oct 22, 2025 · Primary completion Apr 2028
Drug: Brenipatide; Brenipatide and 1 more · For: Asthma
Sites: Tempe, Arizona; Newport Beach, California; Northridge, California · 120 sites in all
- Phase 3b Study in Patients With Severe Asthma Treated With TezepelumabPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07363642 · 400 participants (planned) · Start Jan 28, 2026 · Primary completion Feb 7, 2028
Drug: Tezepelumab · For: Severe Asthma
Sites: Beijing, China; Binzhou, China; Changsha, China · 75 sites in all
Connect Biopharm LLCIndustry
NCT07705737 · 40 participants (planned) · Start Aug 21, 2026 · Primary completion Dec 2026
Drug: Rademikibart · For: Asthma Acute; COPD Exacerbation Acute
Sites: Miami, Florida; St Louis, Missouri · 3 sites in all
Akhilesh JhaAcademic, hospital or other
NCT06488118 · 36 participants (planned) · Start May 24, 2024 · Primary completion Apr 2027
Drug: R848; Saline · For: Innate Immunity; Mucosal Immunity; Asthma and 1 more
Sites: Cambridge, United Kingdom
- A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe AsthmaPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07746687 · 440 participants (planned) · Start Oct 5, 2026 · Primary completion Sep 11, 2029
Drug: JNJ-95597528; Placebo · For: Asthma
Sites: Westminster, California; Boston, Massachusetts; Minneapolis, Minnesota · 19 sites in all
- A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate AsthmaPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07660731 · 133 participants (planned) · Start Jun 17, 2026 · Primary completion Mar 30, 2027
Drug: PF-08103402; Placebo and 1 more · For: Healthy Volunteer Study; Healthy Adults; Healthy Participants and 1 more
Sites: New Haven, Connecticut; Brussels, Belgium
- Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled CorticosteroidsPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06932263 · 540 participants (planned) · Start Mar 26, 2025 · Primary completion Jun 7, 2027
Drug: Tozorakimab; Placebo · For: Asthma
Sites: Bakersfield, California; Huntington Beach, California; La Mesa, California · 223 sites in all
- A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe AsthmaPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07772921 · 1,100 participants (planned) · Start Aug 20, 2026 · Primary completion Jun 1, 2029
Drug: tilrekimig · For: Asthma
Sites: Bakersfield, California; Miami, Florida; White Marsh, Maryland · 16 sites in all
- Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis. MM09-SIT-063.Pivotal-lookingRecruiting
Inmunotek S.L.Industry
NCT07904052 · 250 participants (planned) · Start Feb 24, 2026 · Primary completion Jul 2029
Drug: EP-088_MM09; Placebo · For: Allergic Rhinitis; Allergic Rhinoconjunctivitis; Allergic Asthma
Sites: Coimbra, Portugal; Lisbon, Portugal; Porto, Portugal · 16 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.